Prostate Cancer Therapeutics Market is expected to Grow at 8.05% Through 2030F
Increasing demand for hormonal
therapy along with the rising incidence of chronic diseases are driving the
growth of the market in the forecast period 2026-2030F
According to the TechSci Research report, “Prostate Cancer Therapeutics
Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,
2020-2030F”, Global Prostate Cancer Therapeutics Market was valued at USD 13.45 billion in 2024 and is expected to reach USD 21.23 billion by 2030 with a CAGR of 8.05%.
The factors responsible for the growth of the market are the growing elderly
population, the availability of effective drugs, the prevalence of chronic
diseases, and sedentary lifestyles. Proteome profiling, exome sequencing, and
whole-genome sequencing are just a few of the targeted strategies that market
players have found to be effective for creating novel cures and treatments.
For
instance, in a phase III trial for Olaparib that will enroll nearly 4,000 men
in 2022, tumor genetic testing is expected to be employed to identify patients.
Therefore, the adoption of new screening and diagnostic technologies, along
with government support and initiatives for new therapies to cure prostate
cancer are anticipated to support the growth of the market.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC
on the "Global Prostate Cancer
Therapeutics Market.”
The global Prostate Cancer Therapeutics market is segmented based on treatment
and end user.
Based on End users,The hospital segment is projected to Fastest Growing Segment in the prostate cancer therapeutics market, due to the
availability of advanced medical infrastructure, skilled healthcare
professionals, and comprehensive patient care services. Hospitals often serve
as primary treatment centers for prostate cancer, offering a range of
therapeutic options including surgery, chemotherapy, radiotherapy, and
immunotherapy under one roof. The availability of reimbursement through
government and private healthcare policies makes hospitals a preferred choice
for patients seeking cost-effective and high-quality care. The supporting
sub-segments such as chemotherapy centers, oncology clinics, and ambulatory
surgical centers are anticipated to contribute significantly to market growth.
These facilities provide focused and specialized treatments, enabling faster
patient turnaround and enhancing access to care in both urban and semi-urban
areas. The “Others” category, which includes academic research institutions and
diagnostic centers, will also play a role in driving innovation and expanding
therapeutic options within the prostate cancer treatment landscape.
Major companies operating in the global Prostate Cancer Therapeutics market are:
·
Johnson &
Johnson Services, Inc.
·
Astellas
Pharma Inc.
·
Eli Lilly and
Company
·
Sanofi S.A.
·
Ipsen Pharma
·
Bayer AG
·
AstraZeneca
·
Valeant
Pharmaceuticals International, Inc.
·
Merck &
Co., Inc.
·
Pfizer Inc.
Download Free Sample Report
Customers
can also request for 10% free customization on this report.
Pharmaceutical companies are actively investing in research and development to create novel drugs with improved efficacy and fewer side effects. Collaborations between biotech firms and academic institutions are also accelerating innovation. The market is witnessing a shift toward oral therapies and precision medicine approaches, supported by advancements in genomics and biomarker identification. Despite challenges such as high treatment costs and access disparities, the market outlook remains positive. Emerging economies are presenting new opportunities due to improved healthcare infrastructure and increasing healthcare spending. Theerfore, the prostate cancer therapeutics market is poised for continued expansion, fueled by technological progress and the urgent need for better patient outcomes”, said
Mr. Karan Chechi, Research Director of TechSci Research, a research-based
global management consulting firm.
“Prostate Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment (Hormonal Therapy (Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists, Hormone-Releasing Hormone (LHRH) Agonists, Anti-Androgen), Chemotherapy (Taxotere, Jevtana), Immunotherapy (Provenge), Targeted Therapy (Xofigo), Others), By End User (Hospitals, Specialized Clinics, Ambulatory Surgical Centers, Others), By Region & Competition, 2020-2030F", has
evaluated the future growth potential of Global Prostate Cancer Therapeutics
market and provides statistics & information on market size, structure, and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision-makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in the global Prostate Cancer
Therapeutics market.”
Contact
TechSci Research LLC
420 Lexington Avenue, Suite
300,
New York, United States-
10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com